ERK1/2 mediates the lipopolysaccharide-induced upregulation of FGF-2, uPA, MMP-2, MMP-9 and cellular migration in cardiac fibroblasts

Publication date: Available online 11 April 2019Source: Chemico-Biological InteractionsAuthor(s): Liang-Chi Chen, Marthandam Asokan Shibu, Chung-Jung Liu, Chien-Kuo Han, Da-Tong Ju, Pei-Yu Chen, Vijaya Padma Viswanadha, Chao-Hung Lai, Wei-Wen Kuo, Chih-Yang HuangAbstractMyocardial fibrosis is a critical event during septic shock. Upregulation in the fibrosis signaling cascade proteins such as fibroblast growth factor (FGF), urokinase plasminogen activator (uPA), tissue plasminogen activator (tPA) and activation of matrix metalloproteinases (MMPs) are widely associated with the development of myocardial infarction, dilated cardiomyopathy, cardiac fibrosis and heart failure. However, evidences suggest that the common upstream mediators of fibrosis cascade play little role in cardiac fibrosis induced by LPS; further, it is unknown if LPS directly triggers the expressions and/or activity of FGF-2, uPA, tPA, MMP-2 and MMP-9 in cardiac fibroblasts. In the present study, we treated primary cultures of cardiac fibroblasts with LPS to explore whether LPS upregulates FGF-2, uPA, tPA, MMP-2, MMP-9 and enhance cellular migration. Further the precise molecular and cellular mechanisms behind these LPS induced responses were identified. Inhibition assays on MAPKs using U0126 (ERK1/2 inhibitor), SB203580 (p38 MAPK inhibitor), SP600125 (JNK1/2 inhibitor), CsA (calcineurin inhibitor) and QNZ (NFκB inhibitor) show that LPS-induced upregulation of FGF-2, uPA, MMP-2 and MMP-9 in cardiac fib...
Source: Chemico Biological Interactions - Category: Biochemistry Source Type: research

Related Links:

AbstractOver the recent years, studies have emerged reporting on a strong relationship between the occurrence of malignancy and Takotsubo syndrome. The aim of this systematic review and meta-analysis is to evaluate the predictive value of malignancy for prognosis of Takotsubo syndrome patients. PubMed, EMBASE, Cochrane Library, Web of science, and Scopus were searched until 4 September 2019 for articles concerning association of malignancy with the prognosis of Takotsubo syndrome. A total of ten studies were finally included in this meta-analysis, demonstrating that malignancy was associated with higher mortality in Takots...
Source: Heart Failure Reviews - Category: Cardiology Source Type: research
Authors: Lizardo K, Ayyappan JP, Ganapathi U, Dutra WO, Qiu Y, Weiss LM, Nagajyothi JF Abstract Chagas disease is caused by Trypanosoma cruzi which is endemic in Latin America. T. cruzi infection results in a latent infection with approximately a third of latently infected patients developing chronic Chagas cardiomyopathy (CCM). CCM is a common cause of cardiomyopathy in endemic regions and has a poor prognosis compared to other cardiomyopathies. The factors responsible for the transition from the asymptomatic indeterminate latent stage of infection to CCM are poorly understood. Our previous studies demonstrated th...
Source: Disease Markers - Category: Laboratory Medicine Tags: Dis Markers Source Type: research
Conclusion: The presence of clinically significant TR is associated with an increase in healthcare utilization and expenditures, irrespective of the presence of HF. PMID: 31952454 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - Category: Health Management Tags: J Med Econ Source Type: research
CONCLUSIONS: OFR had an excellent agreement with FFR in consecutive patients with coronary artery disease. OFR was superior than QFR, and much better than conventional morphological parameters in determining physiological significance of coronary stenosis. The diagnostic performance of OFR was not influenced by presence of prior myocardial infarction or implanted stents. PMID: 31951207 [PubMed - as supplied by publisher]
Source: EuroIntervention - Category: Cardiovascular & Thoracic Surgery Tags: EuroIntervention Source Type: research
CONCLUSIONS: Age and female gender are associated with lower CFR, and age with worse CFC in an angiographically non-obstructed coronary artery. CFC seems to be less sensitive to variations in clinical and hemodynamic parameters than CFR, and therefore is a promising tool in contemporary clinical decision making in the cardiac catheterization laboratory. PMID: 31951205 [PubMed - as supplied by publisher]
Source: EuroIntervention - Category: Cardiovascular & Thoracic Surgery Tags: EuroIntervention Source Type: research
Patients with heart failure with reduced ejection fraction (HFrEF) can be treated with mineralocorticoid receptor antagonists (MRAs) and are unlikely to develop hypotension as a result, an analysis of two large randomized trials reveals.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Medscape Today News Source Type: news
Publication date: Available online 17 January 2020Source: Canadian Journal of CardiologyAuthor(s): Sarah AM. Cuddy, Rodney H. FalkAbstractThe systemic amyloidoses are a group of diseases, all characterized by the deposition of amyloid, a material formed from misfolding of proteins, in one or more organs. The 2 commonest forms of amyloidosis, transthyretin amyloidosis (derived from wild-type {ATTRwt} or mutant transthyretin {ATTRm}) and light chain (AL) amyloidosis, derived from abnormal circulating light chains produced by a plasma cell dyscrasia. Both frequently involve the heart, producing an infiltrative cardiomyopathy ...
Source: Canadian Journal of Cardiology - Category: Cardiology Source Type: research
We describe below the design of dal-GenE, a precision medicine, placebo-controlled clinical outcome trial of dalcetrapib in patients with a recent acute myocardial infarction with the unique feature of selecting only those with the AA genotype at rs1967309 in the ADCY9 gene.
Source: American Heart Journal - Category: Cardiology Source Type: research
We read with interest the article by Couselo-Seijas et al. “High released lactate by epicardial fat from coronary artery disease patients is reduced by dapagliflozin treatment” [1]. The use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors (SGLT-2i) is gradually increasing in diabetes mellitus (DM) and heart failure treatment. Increasing pieces of n ovel information are added to the literature on these drugs. We strongly agree with the authors' findings. The article has led us to consider lactate levels in euglycemic (E) diabetic ketoacidosis (DKA) due to SGLT2i use, and the usefulness of metformin and SGLT-2i combination.
Source: Atherosclerosis - Category: Cardiology Authors: Tags: Correspondence Source Type: research
Conclusion: The efficacy and additional benefits of FZF for CCEs were certain according to the high-quality evidence assessed through GRADE. However, the efficacy and additional benefits for the other outcomes were uncertain judging from current studies. In addition, the safety assessment has a great room for improvement. Thus, further research studies are needed to find more convincing proofs. PMID: 31949473 [PubMed]
Source: Evidence-based Complementary and Alternative Medicine - Category: Complementary Medicine Tags: Evid Based Complement Alternat Med Source Type: research
More News: Biochemistry | Cardiology | Cardiomyopathy | Chemistry | Dilated Cardiomyopathy | Heart | Heart Attack | Heart Failure | Molecular Biology | Septic Shock | Study